Journal
NANO TODAY
Volume 16, Issue -, Pages 9-13Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.nantod.2017.08.001
Keywords
Cancer; Hyperthermia; Thermosensitive; Nanomedicine; Liposome; ThermoDox
Categories
Funding
- OGS
- CIHR
- NSERC
- Center for Pharmaceutical Oncology
Ask authors/readers for more resources
Technologies that enable thermal therapy treatments are now clinically viable and most ongoing hyperthermia clinical trials in oncology incorporate chemotherapy. Given the extensive list of chemotherapies that are enhanced by hyperthermia and the ability of thermosensitive nanomedicines to deliver increased amounts of drug to tumors, while not relying on the EPR effect, there is real opportunity for the clinical translation of thermosensitive nanomedicines. To realize this potential, improved thermosensitive nanomedicines encapsulating a wider range of drugs must be developed and advanced into clinical trials. (C) 2017 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available